Robeco Institutional Asset Management B.V. boosted its stake in Chemours Co (NYSE:CC) by 36.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 127,152 shares of the specialty chemicals company’s stock after acquiring an additional 33,980 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Chemours were worth $4,726,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. AI Financial Services LLC acquired a new position in Chemours during the first quarter worth about $2,481,000. Janus Henderson Group PLC grew its position in Chemours by 5.0% during the first quarter. Janus Henderson Group PLC now owns 27,171 shares of the specialty chemicals company’s stock worth $1,010,000 after buying an additional 1,294 shares during the period. First Republic Investment Management Inc. acquired a new position in Chemours during the first quarter worth about $272,000. Cullen Frost Bankers Inc. acquired a new position in Chemours during the first quarter worth about $26,000. Finally, Dupont Capital Management Corp grew its position in Chemours by 647.2% during the first quarter. Dupont Capital Management Corp now owns 116,108 shares of the specialty chemicals company’s stock worth $4,315,000 after buying an additional 100,568 shares during the period. 82.18% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Paul Kirsch sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $38.66, for a total transaction of $386,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Amy Trojanowski sold 13,536 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $38.63, for a total transaction of $522,895.68. Following the sale, the vice president now owns 54,367 shares in the company, valued at approximately $2,100,197.21. The disclosure for this sale can be found here. Insiders sold 101,924 shares of company stock worth $3,924,730 over the last quarter. Company insiders own 2.34% of the company’s stock.
Several research analysts have weighed in on CC shares. ValuEngine lowered shares of Chemours from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 1st. Zacks Investment Research upgraded shares of Chemours from a “sell” rating to a “hold” rating in a research report on Monday, March 18th. SunTrust Banks upped their target price on shares of Chemours to $40.00 and gave the stock a “hold” rating in a research report on Tuesday, February 19th. Susquehanna Bancshares restated a “neutral” rating and set a $37.00 target price on shares of Chemours in a research report on Tuesday, February 19th. Finally, Citigroup restated a “buy” rating and set a $43.00 target price on shares of Chemours in a research report on Wednesday, February 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $46.00.
CC stock opened at $23.93 on Friday. The company has a market capitalization of $3.89 billion, a PE ratio of 4.22, a price-to-earnings-growth ratio of 0.36 and a beta of 2.20. Chemours Co has a 12 month low of $23.36 and a 12 month high of $53.25. The company has a current ratio of 1.81, a quick ratio of 1.04 and a debt-to-equity ratio of 5.18.
Chemours (NYSE:CC) last released its quarterly earnings results on Thursday, May 2nd. The specialty chemicals company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.93 by ($0.30). The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.52 billion. Chemours had a net margin of 12.60% and a return on equity of 87.75%. The firm’s revenue for the quarter was down 20.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.41 earnings per share. Equities analysts anticipate that Chemours Co will post 4.22 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Thursday, May 16th will be given a $0.25 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $1.00 annualized dividend and a dividend yield of 4.18%. Chemours’s dividend payout ratio is presently 17.64%.
Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.
Read More: What is Net Asset Value (NAV)?
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Co (NYSE:CC).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.